2019 was a hard year for cannabis stocks. As the industry struggled to start showing profitability, companies tried their best to strengthen their presence in the U.S. with a great wave of consolidation through M&A.
1. SAFE Banking Act Goes To Senate
In today’s industry, cannabis companies are often denied banking services and accounts from major banks that turn their backs in fear of federal prosecution given cannabis’ designation as a Schedule I narcotic.
As a result of this, most cannabis companies are forced to deal in all cash, forfeiting the security and convenience of banking services. This poses a major hazard to the physical safety of staff, forces extra spending on security and makes the handling of routine accounting tasks like payroll a nightmare.
It’s uncertain whether the bill will hit the president’s desk in 2020. Major roadblocks could be ahead, as both Senate Majority Leader Mitch McConnell (R-Kentucky) and Senate Banking Committee Chairman Mike Crapo (R-Idaho) expressed disagreement with the version of the bill that passed the House.
2. More States Allowing Medical, Recreational Cannabis
2020 is expected to follow this trend. Last year, New Jersey lawmakers approved a ballot for adult-use legalization that will be voted on 2020 and is likely to pass. A similar initiative is currently gathering signatures in Florida to become a referendum that is just as likely to go through.
Further developments for either decriminalization, medical marijuana or adult-use are expected in Arizona, Connecticut, Minnesota, Missouri, Nebraska, New Mexico, North Dakota, and Oklahoma in a domino trend that could put pressure on Congress for full federal legalization in 2021 or 2022.
3. Difficulties Raising Capital Give Way To More Consolidation
As investors become disillusioned with an industry that is not yielding what the “Green Rush” mentality advertised, smaller- and medium-sized companies will have a harder time raising capital. As a result, many companies might choose to be absorbed by larger players in an effort to remain afloat.
From the perspective of the giants, consolidation is a way to secure ground for the competitive market of the future. Expect more M&A in 2020 from companies like Aurora Cannabis ACB 5.96%, Canopy Growth Corp CGC 2.71%, Curaleaf Holdings Inc CURLF 4.35%, Hexo Corp HEXO 3.93% and Tilray Inc TLRY 8.06% both in the U.S. and abroad.
4. Tighter Regulation On CBD Products
For these reasons, according to Cantor Fitzgerald, market experts are expecting Congress to pressure the FDA into developing a clear set of guidelines on CBD production and retail, including manufacturing and supply chain standards.
5. Harder Crackdown On Vaping Could Affect Sales
In 2019, the vaping crisis got out of control. In 2020, local, state and federal authorities are likely to try to regain control of the situation.
With more states pushing for an all-out vaping ban, the fight on bootleg vaping products is likely to continue. Licensed and original products could be affected by bans, and even those that remain legal could have their sales affected as more consumers start to perceive vaping products as hazardous.
With over 2,500 cases of hospitalization as of Dec. 27, the FDA is also expected to increase its vigilance and regulatory efforts.
Image by Unsplash.
Read more from the source: Benzinga.com